KetoSwiss secures USD 4 million in pre-Series A funding to access U.S. market and propel R&D

13.10.2022 14:38, Morgane Ghilardi

The Basel-based startup KetoSwiss is developing a new therapeutic product mitigating neurological diseases such as migraines and brain aging. It has received USD 4 million from multiple investors and partners, led by The William K. Warren Foundation. This will enable the startup to prepare for its upcoming U.S. launch while continuing product development. KetoSwiss was selected as a Venture Leader Life Sciences in 2020, which connects medtech and biotech startups with investors and industry leaders in Boston.

Even though migraines are the third most common disease in the world, there is a significant lack of prevention and treatment options. KetoSwiss has developed a patent-backed therapeutic product that is superior to any current competition. The market potential is significant: 10% of the migraineur target group in the EU, US, Canada, and Japan could deliver USD 1.8 billion in revenue, according to the company's projections.

KetoSwiss was selected to be part of Venture Leaders Life Sciences in 2020. The Venture Leaders program helps Swiss startups to accelerate their global growth. CEO and founder Dr. Elena Gross joined the week-long roadshow in Boston, which enables startups to expand in the U.S. market and build a network by connecting with top investors and industry leaders.

"Despite being at the brink of the Covid pandemic and many meetings still being virtual, the Venture Leaders trip to Boston was an inspiring experience all around," Dr. Gross says, "and it was particularly great to network amongst the other high-quality startups attending, in the beautiful and stimulating Boston environment. I would attend again anytime." 

Thanks to the latest financing round, KetoSwiss is well-positioned to launch its go-to-market brand Brain Ritual in the U.S. market. The investment will also allow the company to reach R&D and clinical development milestones, while also allowing them to conduct exploratory studies with a U.S. partner institution to examine the effects of MigraKet on brain function and its possible implications for patients with depression or other mental health conditions. Further research will be conducted on potential new compounds and molecules.

“We are very happy to close this round with a substantial capital increase that will be crucial for launch-related activities and R&D and further team expansion. This is a very exciting time for KetoSwiss,” says Dr. Gross, who was a chronic migraine sufferer herself.


KetoSwiss CEO & Founder Elena Gross